POST Online Media Lite Edition



 

Female Viagra creator Sprout Pharma to be sold to Valeant for $1 billion

Staff writer |
Valeant Pharmaceuticals International will buy Sprout Pharmaceuticals, whose drug this week became the first approved treatment for low sexual desire in women, for about $1 billion plus milestone payments.

Article continues below






Sprout's pill Addyi was approved on Tuesday by the U.S. Food and Drug Administration (FDA) for pre-menopausal women, after being rejected twice over concerns about its effectiveness and side-effects.

Addyi, popularly known as the "female Viagra", carries a strong warning about potentially dangerous low blood pressure and fainting, especially when taken with alcohol, raising some doubts about its commercial prospects.

Unlike Pfizer's Viagra, which affects blood flow to the genitals, Addyi is meant to activate sexual impulses in the brain.

Sprout, based in Raleigh, N. C., was co-founded in 2011 by husband and wife Cindy and Robert Whitehead. They sold another small drugmaker they founded, Slate Pharmaceuticals.


What to read next

Valeant to trim debt pile with $930 million iNova sale
Valeant in talks to sell Salix unit in $10 billion deal
Valeant completes acquisition of Salix Pharmaceuticals